AWMSG advice
In the absence of a submission from the holder of the marketing authorisation, human normal immunoglobulin (Panzyga®) cannot be endorsed for use within NHS Wales as replacement therapy in adults, and children and adolescents in: primary immunodeficiency syndromes with impaired antibody production; hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed; hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation; hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation; congenital AIDS with recurrent bacterial infections. Immunomodulation in adults, and children and adolescents in: primary immune thrombocytopenia, in patients at high risk of bleeding or prior to surgery to correct the platelet count; Guillain Barré syndrome; Kawasaki disease.
